Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Valutazione dell'efficacia e della sicurezza di Belantamab Mafodotin, Bortezomib e Desametasone rispetto a Daratumumab, Bortezomib e Desametasone in partecipanti con mieloma multiplo recidivato/refrattario (DREAMM 7)

29 ottobre 2026 aggiornato da: GlaxoSmithKline

DREAMM 7: uno studio multicentrico, in aperto, randomizzato di fase III per valutare l'efficacia e la sicurezza della combinazione di Belantamab Mafodotin, Bortezomib e desametasone (B-Vd) rispetto alla combinazione di Daratumumab, Bortezomib e desametasone (D-Vd) ) in partecipanti con mieloma multiplo recidivato/refrattario

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

494

Fase

  • Fase 3

Accesso esteso

Approvato per la vendita al pubblico. Vedi record di accesso esteso.

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • GSK Investigational Site
      • Liverpool, New South Wales, Australia, 2170
        • GSK Investigational Site
      • Newcastle, New South Wales, Australia, 2298
        • GSK Investigational Site
      • St Leonards, New South Wales, Australia, 2065
        • GSK Investigational Site
      • Wollongong, New South Wales, Australia, 2500
        • GSK Investigational Site
    • Queensland
      • Benowa, Queensland, Australia, 4217
        • GSK Investigational Site
      • Herston, Queensland, Australia, 4029
        • GSK Investigational Site
    • South Australia
      • Ashford, South Australia, Australia, 5037
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • GSK Investigational Site
      • Heidelberg, Victoria, Australia, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australia, 3004
        • GSK Investigational Site
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • GSK Investigational Site
      • Nedlands, Western Australia, Australia, 6009
        • GSK Investigational Site
      • Roeselare, Belgio, 8800
        • GSK Investigational Site
    • Brussels Capital
      • Jette, Brussels Capital, Belgio, 1090
        • GSK Investigational Site
      • Woluwé-Saint-Lambert, Brussels Capital, Belgio, 1200
        • GSK Investigational Site
    • Oost-Vlaanderen
      • Ghent, Oost-Vlaanderen, Belgio, 9000
        • GSK Investigational Site
      • Joinville, Brasile, 89201-260
        • GSK Investigational Site
      • Natal, Brasile, 59075-740
        • GSK Investigational Site
      • Rio de Janeiro, Brasile, 22775001
        • GSK Investigational Site
      • São Paulo, Brasile, 04537-080
        • GSK Investigational Site
      • São Paulo, Brasile, 05403-000
        • GSK Investigational Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasile, 90035-903
        • GSK Investigational Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasile, 88020-210
        • GSK Investigational Site
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • GSK Investigational Site
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M4N 3M5
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Canada, H4J 1C5
        • GSK Investigational Site
      • Brno, Cechia, 625 00
        • GSK Investigational Site
      • Hradec Králové, Cechia, 500 05
        • GSK Investigational Site
      • Ostrava, Cechia, 708 52
        • GSK Investigational Site
      • Prague, Cechia, 128 08
        • GSK Investigational Site
      • Beijing, Cina, 100191
        • GSK Investigational Site
      • Beijing, Cina, 100020
        • GSK Investigational Site
      • Changchun, Cina, 130012
        • GSK Investigational Site
      • Guangzhou, Cina, 510060
        • GSK Investigational Site
      • Guangzhou, Cina, 510515
        • GSK Investigational Site
      • Hangzhou, Cina, 310003
        • GSK Investigational Site
      • Jinan, Cina, 250012
        • GSK Investigational Site
      • Nanjing, Cina, 210008
        • GSK Investigational Site
      • Shenyang, Cina, 110001
        • GSK Investigational Site
      • Suzhou, Cina, 215006
        • GSK Investigational Site
      • Tianjin, Cina, 300020
        • GSK Investigational Site
      • Zhengzhou, Cina, 450052
        • GSK Investigational Site
      • Pusan, Corea del Sud, 49241
        • GSK Investigational Site
      • Seongnam-si Gyeonggi-do, Corea del Sud, 13620
        • GSK Investigational Site
      • Seoul, Corea del Sud, 06351
        • GSK Investigational Site
      • Seoul, Corea del Sud, 06591
        • GSK Investigational Site
      • Ulsan, Corea del Sud, 44033
        • GSK Investigational Site
      • Amiens, Francia, 80054
        • GSK Investigational Site
      • Caen, Francia, 14033
        • GSK Investigational Site
      • Nice, Francia, 06200
        • GSK Investigational Site
      • Paris, Francia, 75651
        • GSK Investigational Site
      • Rennes, Francia, 35033
        • GSK Investigational Site
      • Cologne, Germania, 50937
        • GSK Investigational Site
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Germania, 89081
        • GSK Investigational Site
    • Bavaria
      • München, Bavaria, Germania, 81377
        • GSK Investigational Site
      • Würzburg, Bavaria, Germania, 97080
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Germania, 40225
        • GSK Investigational Site
    • Thuringia
      • Jena, Thuringia, Germania, 07747
        • GSK Investigational Site
      • Aichi, Giappone, 467-8602
        • GSK Investigational Site
      • Aichi, Giappone, 441-8570
        • GSK Investigational Site
      • Aomori, Giappone, 030-8553
        • GSK Investigational Site
      • Ehime, Giappone, 790-8524
        • GSK Investigational Site
      • Fukuoka, Giappone, 806-8501
        • GSK Investigational Site
      • Fukuoka, Giappone, 807-8555
        • GSK Investigational Site
      • Fukuoka, Giappone, 810-8563
        • GSK Investigational Site
      • Fukuoka, Giappone, 815-8555
        • GSK Investigational Site
      • Gifu, Giappone, 503-8502
        • GSK Investigational Site
      • Gunma, Giappone, 377-0280
        • GSK Investigational Site
      • Hyōgo, Giappone, 670-8540
        • GSK Investigational Site
      • Kanagawa, Giappone, 247-8533
        • GSK Investigational Site
      • Kanagawa, Giappone, 221-0855
        • GSK Investigational Site
      • Kochi, Giappone, 781-8555
        • GSK Investigational Site
      • Nagano, Giappone, 392-8510
        • GSK Investigational Site
      • Okayama, Giappone, 701-1192
        • GSK Investigational Site
      • Osaka, Giappone, 545-8586
        • GSK Investigational Site
      • Osaka, Giappone, 530-0012
        • GSK Investigational Site
      • Shizuoka, Giappone, 411-8777
        • GSK Investigational Site
      • Athens, Grecia, 11528
        • GSK Investigational Site
      • Thessaloniki, Grecia, 54007
        • GSK Investigational Site
    • East Macedonia and Thrace
      • Alexandroupoli, East Macedonia and Thrace, Grecia, 681 00
        • GSK Investigational Site
      • Jerusalem, Israele, 91120
        • GSK Investigational Site
      • Kfar Saba, Israele, 44281
        • GSK Investigational Site
      • Ramat Gan, Israele, 52621
        • GSK Investigational Site
      • Tel Aviv, Israele, 64239
        • GSK Investigational Site
      • Bergamo, Italia, 24127
        • GSK Investigational Site
      • Bologna, Italia, 40138
        • GSK Investigational Site
      • Brescia, Italia, 25123
        • GSK Investigational Site
      • Catania, Italia, 95123
        • GSK Investigational Site
      • Meldola FC, Italia, 47014
        • GSK Investigational Site
      • Milan, Italia, 20133
        • GSK Investigational Site
      • Ravenna, Italia, 48121
        • GSK Investigational Site
      • Roma, Italia, 00168
        • GSK Investigational Site
      • Siena, Italia, 53100
        • GSK Investigational Site
      • Torino, Italia, 10126
        • GSK Investigational Site
      • Christchurch, Nuova Zelanda, 8011
        • GSK Investigational Site
      • Dunedin, Nuova Zelanda, 9054
        • GSK Investigational Site
      • Takapuna Auckland, Nuova Zelanda, 1309
        • GSK Investigational Site
      • Wellington, Nuova Zelanda, 6021
        • GSK Investigational Site
      • Groningen, Olanda, 9713 GZ
        • GSK Investigational Site
    • South Holland
      • Dordrecht, South Holland, Olanda, 3318 AT
        • GSK Investigational Site
      • Chorzów, Polonia, 41-500
        • GSK Investigational Site
      • Krakow, Polonia, 30510
        • GSK Investigational Site
      • Lodz, Polonia, 93-513
        • GSK Investigational Site
      • Lublin, Polonia, 20-081
        • GSK Investigational Site
      • Lublin, Polonia, 20-090
        • GSK Investigational Site
      • Nowy Sącz, Polonia, 33-300
        • GSK Investigational Site
      • Poznan, Polonia, 60-569
        • GSK Investigational Site
      • Warsaw, Polonia, 02-781
        • GSK Investigational Site
      • Bournemouth, Regno Unito, BH7 7DW
        • GSK Investigational Site
      • Cardiff, Regno Unito, CF14 4XW
        • GSK Investigational Site
      • Dundee, Regno Unito, DD1 9SY
        • GSK Investigational Site
      • Leicester, Regno Unito, LE1 5WW
        • GSK Investigational Site
      • London, Regno Unito, W12 0NN
        • GSK Investigational Site
      • Stoke-on-Trent, Regno Unito, ST4 6QG
        • GSK Investigational Site
      • Sutton, Regno Unito, SM2 5PT
        • GSK Investigational Site
      • Moscow, Russia, 125284
        • GSK Investigational Site
      • Nizhny Novgorod, Russia, 603126
        • GSK Investigational Site
      • Novosibirsk, Russia, 630087
        • GSK Investigational Site
      • Saint Petersburg, Russia, 191024
        • GSK Investigational Site
      • Saint Petersburg, Russia, 197 089
        • GSK Investigational Site
      • Samara, Russia, 443021
        • GSK Investigational Site
      • Saratov, Russia, 410028
        • GSK Investigational Site
      • Ufa, Russia, 450083
        • GSK Investigational Site
      • Barcelona, Spagna, 08035
        • GSK Investigational Site
      • Barcelona, Spagna, 08916
        • GSK Investigational Site
      • Cáceres, Spagna, 10003
        • GSK Investigational Site
      • Gijón, Spagna, 33394
        • GSK Investigational Site
      • L'Hospitalet de Llobrega, Spagna, 08908
        • GSK Investigational Site
      • MOstoles Madrid, Spagna, 28933
        • GSK Investigational Site
      • Madrid, Spagna, 28007
        • GSK Investigational Site
      • Madrid, Spagna, 31008
        • GSK Investigational Site
      • Murcia, Spagna, 30008
        • GSK Investigational Site
      • PamplonaNavarra, Spagna, 31008
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr, Spagna, 28223
        • GSK Investigational Site
      • Salamanca, Spagna, 37007
        • GSK Investigational Site
    • Arizona
      • Yuma, Arizona, Stati Uniti, 85364
        • GSK Investigational Site
    • Kansas
      • Mission, Kansas, Stati Uniti, 66205-2005
        • GSK Investigational Site
    • North Carolina
      • Denver, North Carolina, Stati Uniti, 80128
        • GSK Investigational Site
    • Ohio
      • Blue Ash, Ohio, Stati Uniti, 45242-5665
        • GSK Investigational Site
    • Texas
      • Tyler, Texas, Stati Uniti, 75702
        • GSK Investigational Site
    • Virginia
      • Roanoke, Virginia, Stati Uniti, 24014
        • GSK Investigational Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.

  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Must have at least 1 aspect of measurable disease, defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.

  • Adequate organ function

Exclusion Criteria:

  • Intolerant to daratumumab.
  • Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
  • Corneal epithelial disease.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Belantamab mafodotin e Bortezomib più desametasone (Braccio A)

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Comparatore attivo: Daratumumab e Bortezomib più desametasone (Braccio B)

Proteasome Inhibitor

Synthetic glucocorticoid with anti-tumor activity

Anti-cluster of differentiation 38 [CD-38] monoclonal antibody

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free Survival (PFS)
Lasso di tempo: Up to approximately 41 months

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis.

Up to approximately 41 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Numero di partecipanti con risultati oculari anormali all'esame oftalmico
Lasso di tempo: Fino a 73 mesi
Fino a 73 mesi
Complete Response Rate (CRR)
Lasso di tempo: Up to 73 months

CRR is defined as percentage of participants with a confirmed complete response or better.

Up to 73 months
Overall Response Rate (ORR)
Lasso di tempo: Up to 73 months

ORR is defined as percentage of participants with a confirmed partial response or better.

Up to 73 months
Clinical Benefit Rate (CBR)
Lasso di tempo: Up to 73 months

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Up to 73 months
Duration of Response (DoR)
Lasso di tempo: Up to 73 months

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Up to 73 months
Time to Response (TTR)
Lasso di tempo: Up to 73 months

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Up to 73 months
Time to Progression (TTP)
Lasso di tempo: Up to 73 months

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Up to 73 months
Overall Survival (OS)
Lasso di tempo: Up to 73 months

OS is defined as time from the date of randomization until the date of death due to any cause.

Up to 73 months
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Lasso di tempo: Up to 73 months

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Up to 73 months
Minimal Residual Disease (MRD) Negativity Rate
Lasso di tempo: Up to 73 months

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Up to 73 months
Number of Participants With Adverse Events (AEs)
Lasso di tempo: Up to 73 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Up to 73 months
Number of Participants With Clinically Significant Changes in Hematology Parameters
Lasso di tempo: Up to 73 months

Blood samples will be collected for the analysis of hematology parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Lasso di tempo: Up to 73 months

Blood samples will be collected for the analysis of clinical chemistry parameters.

Up to 73 months
Number of Participants With Clinically Significant Changes in Urine Dipstick
Lasso di tempo: Up to 73 months

Urine samples will be collected for the urine dipstick analysis.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Lasso di tempo: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Lasso di tempo: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Lasso di tempo: Up to 73 months

Blood samples will be collected for PK analysis of belantamab mafodotin.

Up to 73 months
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Lasso di tempo: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Up to 73 months
Titers of ADAs Against Belantamab Mafodotin
Lasso di tempo: Up to 73 months

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Up to 73 months
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Lasso di tempo: Up to 73 months

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Up to 73 months
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Lasso di tempo: Up to 73 months

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Up to 73 months
Change From Baseline in HRQoL as Measured by EORTC IL52
Lasso di tempo: Up to 73 months

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Up to 73 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: GSK Clinical Trials, GlaxoSmithKline

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 maggio 2020

Completamento primario (Effettivo)

2 ottobre 2023

Completamento dello studio (Stimato)

8 ottobre 2029

Date di iscrizione allo studio

Primo inviato

27 gennaio 2020

Primo inviato che soddisfa i criteri di controllo qualità

27 gennaio 2020

Primo Inserito (Effettivo)

29 gennaio 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

29 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 207503
  • 2018 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 2018-003993-29 (Identificatore di registro: EudraCT (EU))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .